RU2373936C2 - Применение метилналтрексона для лечения синдрома раздраженного кишечника - Google Patents

Применение метилналтрексона для лечения синдрома раздраженного кишечника Download PDF

Info

Publication number
RU2373936C2
RU2373936C2 RU2005134359/14A RU2005134359A RU2373936C2 RU 2373936 C2 RU2373936 C2 RU 2373936C2 RU 2005134359/14 A RU2005134359/14 A RU 2005134359/14A RU 2005134359 A RU2005134359 A RU 2005134359A RU 2373936 C2 RU2373936 C2 RU 2373936C2
Authority
RU
Russia
Prior art keywords
pharmaceutical preparation
agent
bowel syndrome
irritable bowel
calcium
Prior art date
Application number
RU2005134359/14A
Other languages
English (en)
Russian (ru)
Other versions
RU2005134359A (ru
Inventor
Томас А. БОЙД (US)
Томас А. БОЙД
Роберт Дж. ИЗРАЭЛ (US)
Роберт Дж. ИЗРАЭЛ
Сукету П. САНГХВИ (US)
Сукету П. САНГХВИ
Original Assignee
Проджиникс Фармасьютикалз, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Проджиникс Фармасьютикалз, Инк. filed Critical Проджиникс Фармасьютикалз, Инк.
Publication of RU2005134359A publication Critical patent/RU2005134359A/ru
Application granted granted Critical
Publication of RU2373936C2 publication Critical patent/RU2373936C2/ru

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/765—Polymers containing oxygen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0031—Rectum, anus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/02—Suppositories; Bougies; Bases therefor; Ovules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
RU2005134359/14A 2003-04-08 2004-04-08 Применение метилналтрексона для лечения синдрома раздраженного кишечника RU2373936C2 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US46160803P 2003-04-08 2003-04-08
US60/461,608 2003-04-08

Publications (2)

Publication Number Publication Date
RU2005134359A RU2005134359A (ru) 2006-06-10
RU2373936C2 true RU2373936C2 (ru) 2009-11-27

Family

ID=33299841

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2005134359/14A RU2373936C2 (ru) 2003-04-08 2004-04-08 Применение метилналтрексона для лечения синдрома раздраженного кишечника

Country Status (10)

Country Link
US (1) US20050004155A1 (https=)
EP (1) EP1617846A1 (https=)
JP (1) JP2006522817A (https=)
CN (1) CN1767830A (https=)
AU (1) AU2004229462A1 (https=)
BR (1) BRPI0409128A (https=)
CA (1) CA2521369A1 (https=)
MX (1) MXPA05010819A (https=)
RU (1) RU2373936C2 (https=)
WO (1) WO2004091622A1 (https=)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2581920C2 (ru) * 2010-11-16 2016-04-20 ПОУЗИ ВИЖНЭРИ СОЛЮШНЗ, ЭлЭлПи Перорально вводимая фармацевтическая композиция для лечения синдрома раздраженного кишечника, содержащая регулятор перистальтики кишечника, средство, которое предотвращает задержку газов, и пищеварительные ферменты, и способ ее получения
US11135264B2 (en) 2016-09-27 2021-10-05 Camurus Ab Formulations containing a somatostatin receptor agonist
US11554229B2 (en) 2013-03-26 2023-01-17 OptiNose Inc. Nasal administration
RU2827066C2 (ru) * 2019-05-07 2024-09-23 Бауш Хелс Айэлэнд Лимитед Композиции жидкой пероральной лекарственной формы метилналтрексона

Families Citing this family (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030158220A1 (en) * 1997-11-03 2003-08-21 Foss Joseph F. Use of methylnaltrexone and related compounds to treat chronic opioid use side effects
US6274591B1 (en) * 1997-11-03 2001-08-14 Joseph F. Foss Use of methylnaltrexone and related compounds
RU2005134364A (ru) * 2003-04-08 2006-06-10 Проджиникс Фармасьютикалз, Инк. (Us) Комбинированное лечение запора
US20040202717A1 (en) 2003-04-08 2004-10-14 Mehta Atul M. Abuse-resistant oral dosage forms and method of use thereof
HRP20150037T4 (hr) 2003-04-08 2022-09-02 Progenics Pharmaceuticals, Inc. Farmaceutske formulacije koje sadrže metilnaltrekson
JP2005239696A (ja) * 2004-01-30 2005-09-08 Daiichi Suntory Pharma Co Ltd 無機物質を配合した医薬硬質カプセル剤
AU2006206454A1 (en) * 2005-01-20 2006-07-27 Progenics Pharmaceuticals, Inc. Use of methylnaltrexone and related compounds to treat post-operative gastrointestinal dysfunction
US9662325B2 (en) 2005-03-07 2017-05-30 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
US8518962B2 (en) 2005-03-07 2013-08-27 The University Of Chicago Use of opioid antagonists
ES2714198T3 (es) * 2005-03-07 2019-05-27 Univ Chicago Uso de antagonistas opioideos para atenuar la proliferación y la migración de células endoteliales
US8524731B2 (en) 2005-03-07 2013-09-03 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
AR057325A1 (es) * 2005-05-25 2007-11-28 Progenics Pharm Inc Sintesis de (s)-n-metilnaltrexona, composiciones farmaceuticas y usos
AR057035A1 (es) 2005-05-25 2007-11-14 Progenics Pharm Inc SíNTESIS DE (R)-N-METILNALTREXONA, COMPOSICIONES FARMACÉUTICAS Y USOS
US20060269507A1 (en) * 2005-05-27 2006-11-30 Susan Fuller Topical ointment compostion and method for making the same
US20080194611A1 (en) * 2005-06-03 2008-08-14 Alverdy John C Modulation of Cell Barrier Dysfunction
US7943328B1 (en) 2006-03-03 2011-05-17 Prometheus Laboratories Inc. Method and system for assisting in diagnosing irritable bowel syndrome
GB0611240D0 (en) * 2006-06-07 2006-07-19 Daniolabs Ltd The treatment of increased sebum production
TWI489984B (zh) * 2006-08-04 2015-07-01 Wyeth Corp 用於非經腸道傳輸化合物之配方及其用途
CO5790164A1 (es) * 2006-08-10 2007-08-31 Procaps S A Composicion farmaceutica solida que incluye en combinacion un agente regulador de la motilidad intestinal y un agente antiflatulento
US20080085524A1 (en) * 2006-08-15 2008-04-10 Prometheus Laboratories Inc. Methods for diagnosing irritable bowel syndrome
US20100094560A1 (en) * 2006-08-15 2010-04-15 Prometheus Laboratories Inc. Methods for diagnosing irritable bowel syndrome
CL2008000905A1 (es) * 2007-03-29 2008-08-22 Progenics Pharm Inc Compuestos derivados de morfina, antagonistas del receptor opioide periferico; metodo de preparacion; composicion farmaceutica; y uso para reducir los efectos de la actividad opioide endogena.
SI2565195T1 (sl) 2007-03-29 2015-09-30 Wyeth Llc Periferalni opioidni receptorji in antagonisti in njih uporaba
MX2009010550A (es) * 2007-03-29 2009-12-14 Progenics Pharm Inc Formas de cristal de bromuro de (r)-n-metilnaltrexona y uso de las mismas.
CN101677997B (zh) * 2007-03-30 2012-05-09 泰奥加制药公司 用于治疗腹泻型和交替型肠易激综合征的κ-阿片剂激动剂
CA2681582C (en) 2007-03-30 2015-07-14 Amgen Inc. Methods of treating bowel disorders
EP2527360B1 (en) 2007-06-04 2015-10-28 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
JP5905198B2 (ja) * 2007-10-01 2016-04-20 ザ ユニヴァーシティー オヴ シカゴ 薬剤誘発性吐き気のオピオイド拮抗薬による治療
US20110111070A1 (en) * 2007-10-25 2011-05-12 Yung-Chi Cheng Use of phy906 as treatment for inflammatory bowel disease and/or irritable bowel syndrome
EP2240489A1 (en) * 2008-02-06 2010-10-20 Progenics Pharmaceuticals, Inc. Preparation and use of (r),(r)-2,2'-bis-methylnaltrexone
EP2278966B1 (en) 2008-03-21 2019-10-09 The University of Chicago Treatment with opioid antagonists and mtor inhibitors
EP2810951B1 (en) 2008-06-04 2017-03-15 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
CA2729582C (en) 2008-07-01 2017-09-19 University Of Chicago Particles containing an opioid receptor antagonist and methods of use
EP3241839B1 (en) 2008-07-16 2019-09-04 Bausch Health Ireland Limited Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders
CA2676881C (en) * 2008-09-30 2017-04-25 Wyeth Peripheral opioid receptor antagonists and uses thereof
DE102009001041A1 (de) * 2009-02-20 2010-08-26 Marien-Apotheke Fulda Ohg Notfallset zur Herstellung eines Arzneimittels zur nasalen Anwendung von Opioiden bei Atemnot
US8829020B2 (en) 2009-07-16 2014-09-09 Mallinckrodt Llc Compounds and compositions for use in phototherapy and in treatment of ocular neovascular disease and cancers
US9040095B2 (en) * 2009-10-14 2015-05-26 Gi Innovations, Pllc Colon cleansing of residual stool and secretions during colonoscopy
PT2722045T (pt) * 2009-11-18 2016-10-18 Helsinn Healthcare Sa Composições para o tratamento de náuseas e vómitos mediadas centralmente
UA123856C2 (uk) 2010-03-11 2021-06-16 Уайт Елелсі Фармацевтичні композиції метилналтрексону та натрію додецилсульфату для перорального введення
CN103002881B (zh) 2010-05-10 2015-09-02 欧洲凯尔特公司 载有活性剂的颗粒与额外活性剂的组合
AU2011252039B2 (en) 2010-05-10 2014-06-12 Euro-Celtique S.A. Pharmaceutical compositions comprising hydromorphone and naloxone
CA2798884C (en) 2010-05-10 2016-09-13 Euro-Celtique S.A. Manufacturing of active-free granules and tablets comprising the same
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
US8778907B2 (en) * 2011-04-27 2014-07-15 Cumberland Pharmaceuticals Lactulose for bowel evacuation
US20130237597A1 (en) * 2012-03-07 2013-09-12 Albert Duoibes Extended-release solid oral dosage form for homeopathic compositions
RU2488824C1 (ru) * 2012-03-20 2013-07-27 Государственное бюджетное образовательное учреждение высшего профессионального образования "Тверская государственная медицинская академия" Министерства здравоохранения Российской Федерации Способ дифференциальной диагностики кишечных инфекций с синдромом гастроэнтерита и алкогольного гастроэнтерита
US10485798B2 (en) 2012-08-22 2019-11-26 Aptapharma Inc. Methylnaltrexone nasal formulations, methods of making, and use thereof
JP6154025B2 (ja) 2012-12-24 2017-06-28 ニューロガストルクス，インコーポレイテッド Ｇｉ管障害を治療するための方法
CA2905435A1 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Compositions useful for the treatment of gastrointestinal disorders
CA2905438A1 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase and their uses
SI3004138T1 (sl) 2013-06-05 2024-07-31 Bausch Health Ireland Limited Ultra čisti agonisti gvanilat ciklaze C, postopek za njihovo pripravo in uporabo
US9044502B2 (en) * 2013-09-18 2015-06-02 Hong Kong Baptist University Chinese medicinal formulation for treating inflammatory bowel disease and the preparation thereof
PT3054977T (pt) * 2013-10-09 2021-10-14 Cedars Sinai Medical Center Diagnóstico e tratamento da síndrome do intestino irritável e da doença inflamatória intestinal
WO2015071380A1 (en) 2013-11-13 2015-05-21 Euro-Celtique S.A. Hydromorphone and naloxone for treatment of pain and opioid bowel dysfunction syndrome
WO2015200369A1 (en) 2014-06-24 2015-12-30 Neurogastrx, Inc. Prodrugs of metopimazine
WO2016057772A1 (en) * 2014-10-09 2016-04-14 Cedars-Sinai Medical Center Methods and systems for distinguishing irritable bowel syndrome from inflammatory bowel disease and celiac disease
WO2016193456A2 (en) * 2015-06-03 2016-12-08 Develco Pharma Schweiz Ag Opioid receptor antagonist for use in treating patients with severe constipation
KR102150548B1 (ko) * 2017-04-25 2020-09-01 대구한의대학교산학협력단 혼합 생약 추출물 및 설파살라진을 유효성분으로 포함하는 대장염 예방 또는 치료용 조성물
WO2018222947A1 (en) * 2017-06-01 2018-12-06 Stc.Unm Bubblyte
IT201700108033A1 (it) * 2017-09-27 2019-03-27 Neilos S R L Composizione per il trattamento della costipazione
IT201700108039A1 (it) * 2017-09-27 2019-03-27 Neilos S R L Composizione per il trattamento della costipazione
WO2019074870A1 (en) * 2017-10-09 2019-04-18 The Broad Institute, Inc. COMPOSITIONS AND METHODS FOR DISCOVERING COMBINATORY DRUG IN DROPLETS OF THE NANOLITRE ORDER
CN108354943A (zh) * 2018-02-13 2018-08-03 南方医科大学南方医院 新生霉素用于制备抑制trpv1表达和转运功能的药物的用途
BR112021022194A2 (pt) * 2019-05-07 2021-12-28 Bausch Health Ireland Ltd Formulações líquidas para dosagem oral de metilnaltrexona
WO2020245214A1 (en) * 2019-06-03 2020-12-10 Bausch Health Ireland Limited Use of methylnaltrexone and rifaximin for treatment of increased gut permeability or associated disorders
US10836757B1 (en) 2020-04-02 2020-11-17 Neurogastrx, Inc. Polymorphic forms of metopimazine
CN118356457B (zh) * 2024-04-29 2025-12-12 河南中医药大学 白头翁汤在增效抗生素抗菌作用中的新用途

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2145958C1 (ru) * 1993-12-08 2000-02-27 Эли Лилли Энд Компани 3,4,4-трехзамещенные пиперидинил-n-алкилкарбоксилаты и промежуточные соединения, способ их получения и фармацевтическая композиция
WO2001032180A3 (en) * 1999-11-01 2001-09-20 Rodeva Ltd Composition for treatment of constipation and irritable bowel syndrome
US6419959B1 (en) * 1996-12-11 2002-07-16 Klinge Pharma Gmbh Galenic composition containing opioid antagonists
US6451806B2 (en) * 1999-09-29 2002-09-17 Adolor Corporation Methods and compositions involving opioids and antagonists thereof

Family Cites Families (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4176186A (en) * 1978-07-28 1979-11-27 Boehringer Ingelheim Gmbh Quaternary derivatives of noroxymorphone which relieve intestinal immobility
JPS5535031A (en) * 1978-09-04 1980-03-11 Shin Etsu Chem Co Ltd Enteric coating composition
US4311833A (en) * 1979-03-06 1982-01-19 Daicel Chemical Industries Ltd. Process for preparing ethylcarboxymethylcellulose
US4322426A (en) * 1980-04-28 1982-03-30 E. I. Du Pont De Nemours And Company 17-Substituted-6-desoxy-7,8-dihydro-6α-methylnoroxymorphone narcotic antagonists
US4377568A (en) * 1981-08-12 1983-03-22 Merck Sharp & Dohme (I.A.) Corp. Preparation of aqueous alcoholic dispersions of pH sensitive polymers and plasticizing agents and a method of enteric coating dosage forms using same
DK150008C (da) * 1981-11-20 1987-05-25 Benzon As Alfred Fremgangsmaade til fremstilling af et farmaceutisk oralt polydepotpraeparat
US4987136A (en) * 1982-03-16 1991-01-22 The Rockefeller University Method for controlling gastrointestinal dysmotility
US4457907A (en) * 1982-08-05 1984-07-03 Clear Lake Development Group Composition and method for protecting a therapeutic drug
US4518433A (en) * 1982-11-08 1985-05-21 Fmc Corporation Enteric coating for pharmaceutical dosage forms
US4462839A (en) * 1983-06-16 1984-07-31 Fmc Corporation Enteric coating for pharmaceutical dosage forms
US4556552A (en) * 1983-09-19 1985-12-03 Colorcon, Inc. Enteric film-coating compositions
EP0143949B1 (en) * 1983-11-01 1988-10-12 TERUMO KABUSHIKI KAISHA trading as TERUMO CORPORATION Pharmaceutical composition containing urokinase
US5266574A (en) * 1984-04-09 1993-11-30 Ian S. Zagon Growth regulation and related applications of opioid antagonists
JPS6229515A (ja) * 1985-07-30 1987-02-07 Shinjiro Tsuji 硬カプセル剤のフイルムコ−テイング方法
US4719215A (en) * 1986-03-07 1988-01-12 University Of Chicago Quaternary derivatives of noroxymorphone which relieve nausea and emesis
US4861781A (en) * 1986-03-07 1989-08-29 The University Of Chicago Quaternary derivatives of noroxymorphone which relieve nausea and emesis
US5597564A (en) * 1986-08-28 1997-01-28 Enzacor Properties Limited Method of administering a microgranular preparation to the intestinal region of animals
KR940000065B1 (ko) * 1986-08-28 1994-01-05 코 사이 잉 토마스 동물 성장 촉진제
US4888346A (en) * 1986-10-07 1989-12-19 Bernard Bihari Method for the treatment of persons infected with HTLV-III (AIDS) virus
US4857833A (en) * 1987-08-27 1989-08-15 Teradyne, Inc. Diagnosis of faults on circuit board
JPH01279895A (ja) * 1988-01-20 1989-11-10 Baker Cummins Pharmaceut Inc オピオイド拮抗剤のグルクロン酸誘導体
US5102887A (en) * 1989-02-17 1992-04-07 Arch Development Corporation Method for reducing emesis and nausea induced by the administration of an emesis causing agent
US4965269A (en) * 1989-12-20 1990-10-23 Ab Hassle Therapeutically active chloro substituted benzimidazoles
NL9002118A (nl) * 1990-09-27 1992-04-16 Medilife Holding Bv Injectiespuit.
JPH04230625A (ja) * 1990-12-27 1992-08-19 Standard Chem & Pharmaceut Corp Ltd 噴霧乾燥したジクロフェナクナトリウムを含み腸溶性の被覆を有するマイクロカプセルからなる微分散した錠剤組成物の製造方法
US5159081A (en) * 1991-03-29 1992-10-27 Eli Lilly And Company Intermediates of peripherally selective n-carbonyl-3,4,4-trisubstituted piperidine opioid antagonists
US5270328A (en) * 1991-03-29 1993-12-14 Eli Lilly And Company Peripherally selective piperidine opioid antagonists
CA2064373C (en) * 1991-03-29 2005-08-23 Buddy Eugene Cantrell Piperidine derivatives
WO1993000077A1 (en) * 1991-06-21 1993-01-07 University Of Cincinnati Orally administrable therapeutic proteins and method of making
US5614219A (en) * 1991-12-05 1997-03-25 Alfatec-Pharma Gmbh Oral administration form for peptide pharmaceutical substances, in particular insulin
USRE36547E (en) * 1992-09-21 2000-02-01 Albert Einstein College Of Medicine Of Yeshiva University Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by exogenous and endogenous opioid agonists
US5512578A (en) * 1992-09-21 1996-04-30 Albert Einstein College Of Medicine Of Yeshiva University, A Division Of Yeshiva University Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by exogenous and endogenous opiod agonists
US5580876A (en) * 1992-09-21 1996-12-03 Albert Einstein College Of Medicine Of Yeshiva University, A Division Of Yeshiva University Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by morphine and other bimodally-acting opioid agonists
US5472943A (en) * 1992-09-21 1995-12-05 Albert Einstein College Of Medicine Of Yeshiva University, Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by morphine and other opioid agonists
US6096756A (en) * 1992-09-21 2000-08-01 Albert Einstein College Of Medicine Of Yeshiva University Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by morphine and other bimodally-acting opioid agonists
ATE143803T1 (de) * 1992-12-22 1996-10-15 Univ Cincinnati Orale verabreichung von immunologischen aktiven biomolekülen und anderen therapeutischen proteinen
US5656290A (en) * 1993-02-26 1997-08-12 The Procter & Gamble Company Bisacodyl dosage form with multiple enteric polymer coatings for colonic delivery
US5391372A (en) * 1993-06-28 1995-02-21 Campbell; Elizabeth Methods of treating colic and founder in horses
WO1995030774A1 (en) * 1994-05-05 1995-11-16 Beckman Instruments, Inc. Oligonucleotide repeat arrays
IT1269826B (it) * 1994-05-24 1997-04-15 Paolo Minoia Uso di antagonisti degli oppiacei e di sali di calcio per la preparazione di medicamenti per il trattamento di forme patologiche endorfino-mediate
US5866154A (en) * 1994-10-07 1999-02-02 The Dupont Merck Pharmaceutical Company Stabilized naloxone formulations
US5965161A (en) * 1994-11-04 1999-10-12 Euro-Celtique, S.A. Extruded multi-particulates
ES2094694B1 (es) * 1995-02-01 1997-12-16 Esteve Quimica Sa Nueva formulacion farmaceuticamente estable de un compuesto de bencimidazol y su proceso de obtencion.
US5614422A (en) * 1995-03-17 1997-03-25 Harris Corporation Process for doping two levels of a double poly bipolar transistor after formation of second poly layer
US6025154A (en) * 1995-06-06 2000-02-15 Human Genome Sciences, Inc. Polynucleotides encoding human G-protein chemokine receptor HDGNR10
US5804595A (en) * 1995-12-05 1998-09-08 Regents Of The University Of Minnesota Kappa opioid receptor agonists
EP0914097B1 (en) * 1996-03-12 2002-01-16 Alza Corporation Composition and dosage form comprising opioid antagonist
US6353004B1 (en) * 1997-07-14 2002-03-05 Adolor Coporation Peripherally acting anti-pruritic opiates
US6559158B1 (en) * 1997-11-03 2003-05-06 Ur Labs, Inc. Use of methylnaltrexone and related compounds to treat chronic opioid use side affects
US5972954A (en) * 1997-11-03 1999-10-26 Arch Development Corporation Use of methylnaltrexone and related compounds
US6274591B1 (en) * 1997-11-03 2001-08-14 Joseph F. Foss Use of methylnaltrexone and related compounds
US20030158220A1 (en) * 1997-11-03 2003-08-21 Foss Joseph F. Use of methylnaltrexone and related compounds to treat chronic opioid use side effects
US6194382B1 (en) * 1999-03-03 2001-02-27 Albert Einstein College Of Medicine Of Yeshiva University Method and composition for treating irritable bowel syndrome using low doses of opioid receptor antagonists
AU6934400A (en) * 1999-08-25 2001-03-19 Barrett R. Cooper Compositions and methods for treating opiate intolerance
US6469030B2 (en) * 1999-11-29 2002-10-22 Adolor Corporation Methods for the treatment and prevention of ileus
US6967075B2 (en) * 2000-04-07 2005-11-22 Schering Corporation HCV replicase complexes
EP1289889B1 (en) * 2000-06-06 2008-07-30 Trojan Technologies Inc. Fluid mixing device
AU2001270134B2 (en) * 2000-06-22 2006-06-15 University Of Iowa Research Foundation Methods for enhancing antibody-induced cell lysis and treating cancer
US20030022909A1 (en) * 2001-06-05 2003-01-30 University Of Chicago Use of methylnaltrexone to treat immune suppression
ES2654819T3 (es) * 2001-10-18 2018-02-15 Nektar Therapeutics Conjugados poliméricos de antagonistas de opioides
CA2475305A1 (en) * 2002-02-04 2004-02-19 Jonathan Moss Use of methylnaltrexone in treating gastrointestinal dysfunction in equines
US20030191147A1 (en) * 2002-04-09 2003-10-09 Barry Sherman Opioid antagonist compositions and dosage forms
US6986901B2 (en) * 2002-07-15 2006-01-17 Warner-Lambert Company Llc Gastrointestinal compositions
WO2004054511A2 (en) * 2002-12-13 2004-07-01 The Regents Of The University Of California Analgesic combination comprising nalbuphine
RU2005134364A (ru) * 2003-04-08 2006-06-10 Проджиникс Фармасьютикалз, Инк. (Us) Комбинированное лечение запора
HRP20150037T4 (hr) * 2003-04-08 2022-09-02 Progenics Pharmaceuticals, Inc. Farmaceutske formulacije koje sadrže metilnaltrekson
EP1682006A4 (en) * 2003-10-29 2011-01-26 Physiosonics Inc METHOD AND DEVICE FOR DETERMINING A MIDDLE LINE OF AN ULTRASONIC LIQUID FLOW
AU2006206454A1 (en) * 2005-01-20 2006-07-27 Progenics Pharmaceuticals, Inc. Use of methylnaltrexone and related compounds to treat post-operative gastrointestinal dysfunction
AR057035A1 (es) * 2005-05-25 2007-11-14 Progenics Pharm Inc SíNTESIS DE (R)-N-METILNALTREXONA, COMPOSICIONES FARMACÉUTICAS Y USOS
AR057325A1 (es) * 2005-05-25 2007-11-28 Progenics Pharm Inc Sintesis de (s)-n-metilnaltrexona, composiciones farmaceuticas y usos

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2145958C1 (ru) * 1993-12-08 2000-02-27 Эли Лилли Энд Компани 3,4,4-трехзамещенные пиперидинил-n-алкилкарбоксилаты и промежуточные соединения, способ их получения и фармацевтическая композиция
US6419959B1 (en) * 1996-12-11 2002-07-16 Klinge Pharma Gmbh Galenic composition containing opioid antagonists
US6451806B2 (en) * 1999-09-29 2002-09-17 Adolor Corporation Methods and compositions involving opioids and antagonists thereof
WO2001032180A3 (en) * 1999-11-01 2001-09-20 Rodeva Ltd Composition for treatment of constipation and irritable bowel syndrome

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
ГРИГОРЬЕВ П.Я. и др. Клиническая гастроэнтерология, МИА. - М., 2001, с.491-492. ШЕПТУЛИН А.А. Диагностика и лечение нарушений моторики желудочно-кишечного тракта, 26-Apr-2000, [он-лайн] [Найдено 2007.06.10] найдено из Интернета http://www.kuban.su/medicine/shtm/baza/razno/motor.htm. *

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2581920C2 (ru) * 2010-11-16 2016-04-20 ПОУЗИ ВИЖНЭРИ СОЛЮШНЗ, ЭлЭлПи Перорально вводимая фармацевтическая композиция для лечения синдрома раздраженного кишечника, содержащая регулятор перистальтики кишечника, средство, которое предотвращает задержку газов, и пищеварительные ферменты, и способ ее получения
US11554229B2 (en) 2013-03-26 2023-01-17 OptiNose Inc. Nasal administration
US11135264B2 (en) 2016-09-27 2021-10-05 Camurus Ab Formulations containing a somatostatin receptor agonist
US11241476B2 (en) 2016-09-27 2022-02-08 Camurus Ab Mixtures and formulations comprising an alkyl ammonium EDTA salt
US11564968B2 (en) 2016-09-27 2023-01-31 Camurus Ab Formulations containing a somatostatin receptor agonist
US12257282B2 (en) 2016-09-27 2025-03-25 Camarus Ab Mixtures and formulations
RU2827066C2 (ru) * 2019-05-07 2024-09-23 Бауш Хелс Айэлэнд Лимитед Композиции жидкой пероральной лекарственной формы метилналтрексона

Also Published As

Publication number Publication date
CA2521369A1 (en) 2004-10-28
EP1617846A1 (en) 2006-01-25
WO2004091622A1 (en) 2004-10-28
BRPI0409128A (pt) 2006-03-28
RU2005134359A (ru) 2006-06-10
US20050004155A1 (en) 2005-01-06
AU2004229462A1 (en) 2004-10-28
JP2006522817A (ja) 2006-10-05
CN1767830A (zh) 2006-05-03
MXPA05010819A (es) 2006-03-30

Similar Documents

Publication Publication Date Title
RU2373936C2 (ru) Применение метилналтрексона для лечения синдрома раздраженного кишечника
US20040259899A1 (en) Combination therapy for constipation
US20080176955A1 (en) Combined administration of benzonatate and guaifenesin
EP0888111B1 (en) Modified release multiple-units dosage composition
TWI481410B (zh) 克羅非莫(crofelemer)用於治療與腹瀉型腸躁症(d-IBS)相關聯之腹痛及腹部不適的醫藥用途
US8513439B2 (en) Antidepressant oral pharmaceutical compositions
AU2011276170B2 (en) Novel gastro- retentive dosage forms comprising a GABA Analog and an opioid
JP6494529B2 (ja) ピロリ菌治療用医薬組成物
US8455667B2 (en) Duloxetine compositions in the form of a powder for suspension in a liquid
EP1086701B1 (en) Simethicone containing laxative composition
WO2000006128A1 (fr) Preparation capable de liberer un medicament au niveau d'un site cible dans l'intestin
EP1172100A1 (en) Oral solid pharmaceutical formulations with ph-dependent multiphasic release
JP6566638B2 (ja) メサラミンの放出制御固形製剤
EP2861223A1 (en) Compositions and methods for transmucosal absorption
US11278498B2 (en) Sustained release solid dosage forms for modulating the colonic microbiome
ZA200309048B (en) Pharmaceutical formulation for the efficient administration of apomorphine, 6aR-(-)-N-propyl-norapomorphine and their derivatives and pro-drugs thereof.
EP1607087A1 (en) Medicinal oral preparations for colon delivery, medicinal oral preparations for treating colon cancer and medicinal oral preparations for treating colitis
EP1044681A2 (en) Sustained release carbamazepine formulation
JP2003201256A (ja) 大腸送達性経口医薬製剤、大腸癌治療用経口医薬製剤および大腸炎治療用経口医薬製剤
EP2481403A1 (en) Pharmaceutical combination of otilonium and trimebutine
EP1216032B1 (en) Oral controlled release formulations
ZA200202293B (en) Orally distintegrating composition comprising mirtazapine.
JP2008535905A (ja) 慢性便秘を治療するためのアカルボース方法と製剤
CN101797253B (zh) 一种岩白菜素、盐酸西替利嗪复方口服剂型
JPH05262767A (ja) 持続性製剤